Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ifetroban - Cumberland Pharmaceuticals

Drug Profile

Ifetroban - Cumberland Pharmaceuticals

Alternative Names: BMS 18029; BMS 180291; BMS 180291A; BMS-180291-02; Boxaban; CPI 211; Hepatoren; Portaban; Vasculan

Latest Information Update: 04 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Bristol-Myers Squibb; Cumberland Pharmaceuticals; Vanderbilt-Ingram Cancer Center
  • Class Antiasthmatics; Antihypertensives; Antineoplastics; Antiplatelets; Heterocyclic bicyclo compounds; Oxazoles; Skin disorder therapies; Small molecules
  • Mechanism of Action Thromboxane A2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Asthma; Cardiomyopathies; Hepatorenal syndrome; Portal hypertension; Solid tumours; Systemic scleroderma
  • Discontinued Coronary thrombosis; Peripheral vascular disorders; Thrombosis

Most Recent Events

  • 02 Dec 2019 Phase-II clinical trials in Cardiomyopathies in USA (unspecified route)
  • 24 Sep 2019 Preclinical trials in Cardiomyopathies in USA (unspecified route)
  • 24 Sep 2019 The US FDA clears a clinical trial application for a phase II trial in Cardiomyopathy (associated with Duchenne muscular dystrophy) (In children, In adolescents, In adults, In the elderly)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top